GB9218322D0 — Therapeutic agents

USPTO Abstract

PCT No. PCT/EP93/02097 Sec. 371 Date Jan. 31, 1995 Sec. 102(e) Date Jan. 31, 1995 PCT Filed Aug. 4, 1993 PCT Pub. No. WO94/05661 PCT Pub. Date Mar. 17, 1994Compounds of the formula <IMAGE> and pharmaceutically acceptable salts thereof, wherein R1 is H, C1-C4 alkyl CN or CONR4R5; R2 is C2-C4 alkyl; R3 is SO2NR6R7, NO2, NH2, NHCOR8 NHSO2R8 or N(SO2R8)2; R4 and R5 are each independently selected from H and C1-C4 alkyl; R6 and R7 are each independently selected from H and C1-C4 alkyl optionally substituted with CO2R9, OH, pyridyl 5-isoxazolin-3-onyl, morpholino or 1-imidazolidin-2-onyl; or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino, morpholino, 1-pyrazolyl or 4-(NR10)-1-piperazinyl group wherein any of said groups may optionally be substituted with one or two substituents selected from C1-C4 alkyl, CO2R9, NH2 and OH; R8 is C1-C4 alkyl or pyridyl; R9 is H or C1-C4 alkyl; and R10 is H, C1-C4 alkyl or (hydroxy) C2-C3 alkyl; are selected cGMP PDE inhibitors useful in the treatment of, inter alia, cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.